Advertisement

Endogenous Endophthalmitis from the Prospective of Integration Medicine

  • Hong Wang
  • Wenbin Wei
  • Lin Shen
  • Ying Hong
Chapter
Part of the Advances in Visual Science and Eye Diseases book series (AVSED, volume 3)

Abstract

Endophthalmitis is the acute suppurative inflammation in uvea and retina, with rapid onset, severe symptoms, and poor prognosis. Definite diagnosis and effective treatment on early stage play key roles in the prognosis. As endogenous endophthalmitis originates from suppurative inflammation in other parts of our body with hidden primary lesions, and is found less common in clinical practice, ophthalmologists might easily confuse it with uveitis caused by the immune disease, which not only causes a high misdiagnosis rate, but also delays the best opportunity for diagnosis and treatment. Endogenous endophthalmitis is a focus secondary to systemic infection, requiring ophthalmologists to strengthen the understanding of systemic infection and detailed history taking, to learn that whether the primary lesions exist or not? Where is the primary lesion? Which kind of pathogen causes the infection? How to apply the antibiotics? This section analyzes the cases of endogenous endophthalmitis in Tongren Hospital, and summarizes the experience in etiology, clinical manifestation, diagnosis points, treatment, prognosis, etc. of endogenous endophthalmitis. Ophthalmologists are supposed to take endogenous endophthalmitis from the perspective of integrative medicine, identify endogenous endophthalmitis through the history and pathogen examination, and clarify the cause and pathogens, and thus target the selection of antibiotics, taking the systemic inflammation control into account. Ophthalmologists should strengthen the understanding of endogenous endophthalmitis, make diagnosis at early stage and apply the effective drug timely, and improve the prognosis of endogenous endophthalmitis.

References

  1. 1.
    Connell PP, O’Neill EC, Fabinyi D, et al. Endogenous endophthalmitis: 10-year experience at a tertiary referral centre. Eye (Lond). 2011;25(1):66–72.CrossRefGoogle Scholar
  2. 2.
    Jackson TL, Eykyn SJ, Graham EM, et al. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):403–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Chung KS, Kim YK, Song YG, et al. Clinical review of endogenous endophthalmitis in Korea: a 14-year review of culture positive cases of two large hospitals. Yonsei Med J. 2011;52(4):630–4.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore). 2003;82(2):97–105.CrossRefGoogle Scholar
  5. 5.
    Lim HW, Shin JW, Cho HY, et al. Endogenous endophthalmitis in the Korean population: a six-year retrospective study. Retina. 2014;34(3):592–602.CrossRefPubMedGoogle Scholar
  6. 6.
    Pinna A, Cara F, Zanetti S, et al. Endogenous Rhodotorula minuta and Candida albicans endophthalmitis in an injecting drug user. Br J Ophthalmol. 2001;85(6):759.CrossRefPubMedGoogle Scholar
  7. 7.
    Chhablani J. Fungal endophthalmitis. Exp Rev Anti Infect Ther. 2011;9(12):1191–201.CrossRefGoogle Scholar
  8. 8.
    Schiedler V, Scott IU, Flynn HW. Culture-proven endogenous endophthalmitis clinical features and visual acuity outcomes. Am J ophthalmol. 2004;137(4):725–31.PubMedGoogle Scholar
  9. 9.
    Chen KJ, Wu WC, Sun MH, et al. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol. 2012;154(1):213–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Arevalo JF, Jap A, Chee SP, et al. Endogenous endophthalmitis in the developing world. Int Ophthalmol Clin. 2010;50(2):173–87.CrossRefPubMedGoogle Scholar
  11. 11.
    Sridhar J, Flynn HW Jr, Kuriyan AE, et al. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect. 2013;3(1):60.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 2000;30(1):14–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Congrong L, Shaohua P, Dong L, et al. A hospital acquired infection of deep fungus: a clinical investigation and drug resistance. Chin J Nosocomiol. 2002;12(7):485–7.Google Scholar
  14. 14.
    Pfaller MA, Messer SA, Hollis RJ, et al. Trends in species distribution and susceptibility to fluconazole among blood steam isolates of Candida species in the United states. Diagn Microbiol Infect Dis. 1999;33(4):217–22.CrossRefPubMedGoogle Scholar
  15. 15.
    Leibovitch I, Lai T, Raymond G, et al. Endogenous endophthalmitis: a 13-year review at a tertiary hospital in South Australia. Scand J Infect Dis. 2005;37(3):184–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Wong JS, Chan TK, Lee HM. Endogenous bacterial endophthalmitis. An east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology. 2000;107(8):1483–91.CrossRefPubMedGoogle Scholar
  17. 17.
    Peizeng Y. Clinical uveitis. Beijing: People’s Medical Publishing House; 2004. p. 677–8.Google Scholar
  18. 18.
    Cornut PL, Chiquet C. Endogenous bacterial endophthalmitis. J Fr Ophthalmol. 2011;34(1):51–7.CrossRefGoogle Scholar
  19. 19.
    Lee JH, Kim JS, Park YH. Diagnosis and treatment of postpartum Candida endophthalmitis. J Obstet Gynaecol Res. 2012;38(9):1220–2.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanaka M, Kobayashi Y, Takebayashi H, et al. Analysis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis: a retrospective 12-year study of 79 eyes of 46 patients. Retina. 2001;21(3):203–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Okada AA, Johnson RP, Liles WC. Endogenous bacterial endophthalmitis. Report of a 10-year retrospective study. Ophthalmology. 1994;101(5):832–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Greenwald MJ, Wohl LG, Sell CH. Metastatic bacterial endophthalmitis: a contemporary reappraisal. Surv Ophthalmol. 1986;31(2):81–101.CrossRefPubMedGoogle Scholar
  23. 23.
    Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers. 1996;27(12):1012–8.PubMedGoogle Scholar
  24. 24.
    Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308–29.CrossRefPubMedGoogle Scholar
  25. 25.
    Akler ME, Vellend H, McNeely DM, et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis. 1995;20(3):657–64.CrossRefPubMedGoogle Scholar
  26. 26.
    Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52(5):648–53.CrossRefPubMedGoogle Scholar
  27. 27.
    Penk A, Pittrow L. Status of fluconazole in the therapy of endogenous Candida endophthalmitis. Mycoses. 1998;2:41–4.Google Scholar
  28. 28.
    Michal W, Olena W, Wojciech O. Bilateral endogenous fungal endophthalmitis. Int Ophthalmol. 2014;34(2):321–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Shen X, Xu G. Vitrectomy for endogenous fungal endophthalmitis. Ocul Immunol Inflamm. 2009;17(3):148–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2020

Authors and Affiliations

  • Hong Wang
    • 1
    • 2
  • Wenbin Wei
    • 1
    • 2
  • Lin Shen
    • 1
    • 2
  • Ying Hong
    • 3
  1. 1.Beijing Tongren Eye Center, Beijing Tongren HospitalCapital Medical UniversityBeijingChina
  2. 2.Beijing Ophthalmology and Visual Sciences Key LaboratoryBeijingChina
  3. 3.Department of OphthalmologyPeking University Third HospitalBeijingChina

Personalised recommendations